Skip to content
Open access

Tumor suppressor syntaxin binding protein 1 regulates alternative splicing of DNA repair genes related to radiation sensitivity in breast cancer cells

Aug 2026 · Oncology Letters · Vol 32 · 0 citations · 51 references
Medicine

TL;DR

It is discovered that STXBP1 regulates global gene expression and alternative splicing profiles in MDA-MB-231 cells by modulating 111 differentially expressed genes and 1,161 regulated alternative splicing events.

Abstract

As the most aggressive subtype of breast cancer, triple-negative breast cancer (TNBC) is frequently treated with radiotherapy. Downregulation of syntaxin binding protein 1 (STXBP1) gene expression is notably associated with poor prognosis in patients with breast cancer and its protein expression level is associated with tumor radioresistance. However, the precise molecular mechanisms by which STXBP1 regulates breast cancer pathogenesis and radiotherapy resistance remain to be elucidated. In the present study, STXBP1 was overexpressed in MDA-MB-231 cells to investigate its effects on cell proliferation and apoptosis. Transcriptomic sequencing (RNA-sequencing; RNA-seq) was performed to identify differentially expressed genes and alternative splicing events regulated by STXBP1. Additionally, a publicly available RNA-seq dataset (GSE189495) associated with breast cancer radiotherapy, including three fractionally irradiated 20 Gy and three age-matched control MCF-7 cell samples were analyzed to identify radiotherapy-associated alternative splicing alterations. Integrated analysis of these two datasets was conducted to explore the potential mechanisms underlying STXBP1-mediated radiotherapy response in breast cancer. Key gene expression changes and alternative splicing events were validated using reverse transcription-quantitative (RT-q) PCR. In MDA-MB-231 cells, the overexpression of STXBP1 notably inhibited cell proliferation and enhanced levels of apoptosis. Through an analysis of RNA-seq data, the present study discovered that STXBP1 regulates global gene expression and alternative splicing profiles in MDA-MB-231 cells by modulating 111 differentially expressed genes and 1,161 regulated alternative splicing events. STXBP1 plays a key role in regulating the splicing patterns of numerous DNA repair-related genes, including USP48 and PLEC. In addition, the present study conducted an overlap analysis on the transcriptome data from radiotherapy-treated MCF-7 cells alongside the dataset generated in the present study, which revealed 21 alternative splicing events associated with radiotherapy. Notably, these include the DNA repair-related gene UBE2I, and its expression pattern has been confirmed through RT-qPCR. The present study systematically delineated the downstream targets and functional mechanisms of STXBP1 in breast cancer cells, revealing its antitumor molecular role. Moreover, STXBP1 may be associated with radiation sensitivity by regulating the alternative splicing of genes associated with DNA repair. These molecular targets, such as UBE2I, hold potential as novel therapeutic avenues for breast cancer treatment, particularly for TNBC.

Read PDF

Similar papers

Open access Sep 2026

LINC00536 regulates transcriptional repressor TRPS1 in breast cancer

The findings imply that human LINC00536/TRPS1 serves as a novel and early biomarker of cancer progression and a potential therapeutic target for breast cancer.

Rui Zhang, Jia-Rong Li, D. Badescu et al. · 0 citations
Open access Jul 2026

Identification of RNA binding proteins targeting TP53, RB1 and PTEN in colorectal cancer as potential biomarkers for diagnosis, drug resistance, sensitivity and prognosis

Twenty-two RBPs were identified as candidate binding-associated regulators of key tumor suppressors and seven RBPs involved in prominent pathways were identified as candidate prognostic biomarkers requiring further validation in independent cohorts before any clinical application can be considered in CRC, although thes...

A. Asadi, Mehrdad Hashemi, M. Peymani et al. · 0 citations
Open access Jul 2026

GPR19 Drives Cell Cycle Progression via ERK-Dependent FOXM1 Activation in p53-Mutant Breast Cancer.

GPR19 functions as a novel oncogenic driver and clinically relevant biomarker in breast cancer, particularly in TP53-mutant and TNBC subsets, and was significantly upregulated in TP53-mutant breast cancer, primary tumors, and especially TNBC.

Jihan Qiu, Cheng Tian, Hanzhi Li et al. · 0 citations
Open access Jul 2026

Apoptosis-related TP53AIP1 inhibits breast cancer progression by inactivating the MAPK pathway and serves as a novel prognostic biomarker.

It is suggested that TP53AIP1 may serve as a potential prognostic biomarker and tumor-suppressive candidate in breast cancer, with its effects at least partly associated with MAPK pathway attenuation.

Meihai Deng, Xueting Wu, J. Bai et al. · 0 citations
Open access Jul 2026

DNA methylation reprogramming of gene regulatory elements is associated with lung metastasis in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is a major cause of cancer mortality, with distant metastases, particularly to the lungs, presenting a significant clinical challenge. While epigenetic mechanisms like DNA methylation (DNAm) are known to influence TNBC progression, their association with lung metastasis remains unde...

Andrés F Bedoya-López, Sandra Íñiguez-Muñoz, Javier I. J. Orozco et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.